NCT01146795

Who might be able to join this trial:

• You have been diagnosed with, or are suspected to have, advanced-stage ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (advanced stage means it has spread widely in the abdomen or beyond).
• Your cancer has been confirmed or is strongly suspected to be a type called "epithelial" cancer through a tissue or fluid sample.
• You are reasonably active and able to care for yourself, or only have mild limitations in daily activity (confirm with trial site).
• If you have previously been treated with a certain type of chemotherapy drug called an anthracycline, you must have had a recent heart scan before joining.
• Your blood counts are healthy enough — including white blood cells, platelets, and red blood cells — at levels the trial team considers safe.
• Your kidneys are functioning well enough, based on blood test results.
• Your liver is functioning well enough, based on blood test results.
• You do not have significant nerve damage (such as numbness or weakness) beyond a mild level.
• Your blood clotting levels are within an acceptable range (or stable if you are on a blood-thinning medication like warfarin).
• Your cancer can be measured on scans or tests.
• A specific blood marker for ovarian cancer (called CA-125) is at or above a certain level (70 units/mL).
• A specialist surgeon has assessed you and believes you are likely fit enough to have surgery to remove as much cancer as possible after 3 rounds of chemotherapy.
• You have signed a consent form agreeing to take part and allowing your health information to be used.
• You may be taking hormone replacement therapy (estrogen with or without progestin).

Who may not be able to join:

• You have already had surgery related to your cancer, other than a small biopsy or fluid sample.
• You have already received chemotherapy, immunotherapy, radiation, hormone therapy, or biological therapy for this cancer.
• Your cancer is a borderline type, a returning (recurrent) cancer, or a non-epithelial type of ovarian cancer.
• A certain ratio between two blood markers (CA-125 and CEA) is below a specific level (confirm with trial site).
• You have had another type of cancer (other than certain common skin cancers) within the last five years.
• You have active hepatitis or severe liver disease.
• You have a serious wound, ulcer, or bone fracture that is not healing, or you have had an abdominal fistula or internal abdominal infection in the last 6 months.
• You have a history of a hole or tear forming in your bowel or digestive tract (gastrointestinal perforation).
• There is unexplained free air (gas) inside your abdomen showing on scans.
• You have signs of a blocked bowel, or you are receiving nutrition through a tube or a drip.
• You have active bleeding, a bleeding disorder, or a tumor that is growing into or around major blood vessels.
• You have a brain tumor, poorly controlled seizures, brain metastases (cancer that has spread to the brain and is not fully treated), or you have had a stroke or related brain event within the last 6 months.
• You have significant heart or blood pressure problems, including uncontrolled high blood pressure, a recent heart attack or unstable chest pain (within the last 6 months), moderate-to-severe heart failure, serious irregular heartbeat requiring medication, or significant disease in the blood vessels of your legs or arms.
• You have had a stroke within the last 6 months.
• You have a known allergy to bevacizumab or similar laboratory-made antibody drugs (confirm with trial site).
• You have a significant amount of protein in your urine, based on a urine test.
• You have had a severe high blood pressure crisis or high-blood-pressure-related brain swelling.
• You have coughed up a meaningful amount of blood (roughly half a teaspoon or more) within the last month.
• You have had a major operation, significant injury, or open biopsy within 28 days before starting the study drug bevacizumab, or you are expected to need major surgery during the trial; or you have had a needle (core) biopsy within 7 days before starting bevacizumab.
• Your general health and activity level is severely limited (Performance Status Grade 3 or